TENAYA THERAPEUTICS, INC. TNYA 深 滬
等待開盤 12-16 09:30:00 美东时间
0.797
-0.053
-6.24%
華盛通- 最 高0.904
- 今 開0.90
- 成交量 1626.20万股
- 最 低 0.79
- 昨 收 0.85
- 總市值 1.33亿
- 52周最高 2.35
- 市盈率 靜 --
- 換手率 9.74%
- 52周最低 0.36
- 委 比 98.90%
- 總股本 1.67亿
- 歷史最高 32.00
- 量 比 1.10
- 振 幅 13.41%
- 歷史最低 0.36
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
Tenaya Stock Plunges After $60 Million Equity Offering
Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.
12-13 02:56
Tenaya Therapeutics shares are trading lower after the company announced a proposed public offering.
Tenaya Therapeutics shares are trading lower after the company announced a prop...
12-12 05:24
Tenaya Therapeutics Receives FDA Clearance To Resume MyPEAK‑1 Trial Of TN‑201 For MYBPC3‑Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
12-12 05:07
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Tenaya Therapeutics Q3 EPS $(0.12) Beats $(0.15) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 22.58 percent. This is a 60 percent increase over losses of $(0.30) per share from
11-10 20:15
Tenaya Therapeutics To Give Two Late-breaking Oral Presentations At The American Heart Association 2025 Scientific Sessions Taking Place November 7-10, 2025
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,
11-05 06:39
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
<p>Tenaya Therapeutics announced that CEO Faraz Ali will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on October 14, 2025. Additionally, management will host virtual 1x1 meetings on October 15. The fireside chat webcast and replay can be accessed via Tenaya's website under the Investors section. Tenaya focuses on developing curative therapies for heart diseases, with a pipeline including gene therapie...
10-09 20:05
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
<p><p align="left">Tenaya Therapeutics的CEO Faraz Ali将参加10月6日的Cell & Gene Meeting on the Mesa会议，参与"Future Horizons"小组讨论和公司展示。此外，他在10月21日的Chardan Annual Genetic Medicines Conference上将参与"Gene Therapies for Genetic Cardiac Diseases"小组讨论。这两场会议均提供网络直播，直播存档可在Tenaya官网保存约30天。Tenaya专注于心脏疾病基因治疗，旗下有多个临床阶段候选药物。如需更多信息，请访问公司官网或联系相关人员。</p></p>
10-02 20:05
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics granted stock options to purchase 202,000 shares of its common stock to two new non-executive employees. The options, exercisable at $1.20 per share, vest over four years and are subject to the company's 2024 Inducement Equity Incentive Plan. The options, granted as inducements under NASDAQ Listing Rule 5635(c)(4), reflect the company's mission to develop curative therapies for heart disease.
09-18 20:05
